11 November 2026
DLA Piper advises IMVIONIX on US and Canadian commercial rights for retinal therapy
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Lauren Murdza Lead | DLA Piper | Partner | Not stated | Philadelphia |
| James McGraw Lead | DLA Piper | Partner | Not stated | Washington, DC |
| Shai Wood | DLA Piper | Associate | Not stated | Philadelphia |
| Andrew Gilbert | DLA Piper | Partner | Not stated | Short Hills/New York |
| Lisa Haile | DLA Piper | Partner | Not stated | San Diego |
| W. Kurtis Weaver | DLA Piper | Partner | Not stated | Boston |
| Christopher Mikson | DLA Piper | Partner | Not stated | Washington, DC/Philadelphia |
| William Bartow | DLA Piper | Partner | Not stated | Not stated |
| Andrew Dietrick | DLA Piper | Associate | Not stated | Philadelphia |
6 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- IMVIONIX Inc.Buy-side
- Counterparties
- Novartis (Sell-side)